Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6

Journal of Biological Chemistry

Volumn 287, Issue 49, 2012, Pages 41406-41416

  Cahill, Karyn B ^a   Quade, Jonathan H ^a   Carleton, Karen L ^b   Cote, Rick H ^a  

^a UNIVERSITY OF NEW HAMPSHIRE   (United States)

^b Bldg 142   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; ADVERSE SIDE EFFECTS; AMINO ACID RESIDUES; BINDING AFFINITIES; CATALYTIC EFFICIENCIES; CLASS I; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES; HETEROLOGOUS EXPRESSION; MISFOLDING; PHARMACOLOGICAL DIFFERENCES; PHOSPHODIESTERASES; PROTEIN SEQUENCES; PROTEIN SOLUBILITY; SELECTIVE INHIBITORS; SITE DIRECTED MUTAGENESIS; STRUCTURAL BASIS; STRUCTURAL ELEMENTS; STRUCTURAL HOMOLOGY; TADALAFIL; VARDENAFIL; VASCULAR SMOOTH MUSCLES; VISUAL TRANSDUCTION;

AMINO ACIDS; BINDING ENERGY; BINDING SITES; NUCLEOTIDES; PROTEINS; TRACE ANALYSIS;

ESTERS;

ASPARAGINE; ASPARTIC ACID; GLUTAMIC ACID; ISOLEUCINE; LEUCINE; METHIONINE; PHENYLALANINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PROLINE; TADALAFIL; TRYPTOPHAN; VALINE; VARDENAFIL;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; MOLECULAR EVOLUTION; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; STRUCTURAL HOMOLOGY;

AMINO ACID SEQUENCE; AMINO ACIDS; CARBOLINES; CATALYTIC DOMAIN; CLONING, MOLECULAR; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 6; DRUG DESIGN; ENZYME INHIBITORS; EVOLUTION, MOLECULAR; EYE PROTEINS; HUMANS; IMIDAZOLES; KINETICS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROTEIN BINDING; RETINA; SEQUENCE HOMOLOGY, AMINO ACID; SULFONES; TRIAZINES;

VERTEBRATA;

EID: 84870315904     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.389189     Document Type: Article

References (41)

1. Conti, M., and Beavo, J. (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases. Essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511
2. Cote, R. H. (2006) in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo, J. A., Francis, S. H., and Houslay, M. D., eds) pp. 165-193, CRC Press, Boca Raton, FL
3. Cote, R. H. (2004) Characteristics of photoreceptor PDE (PDE6). Similarities and differences to PDE5. Int. J. Impot. Res. 16, S28-S33
4. Kameni Tcheudji, J. F., Lebeau, L., Virmaux, N., Maftei, C. G., Cote, R. H., Lugnier, C., and Schultz, P. (2001) Molecular organization of bovine rod cGMP-phosphodiesterase 6. J. Mol. Biol. 310, 781-791 (Pubitemid 32695695)
5. Kajimura, N., Yamazaki, M., Morikawa, K., Yamazaki, A., and Mayanagi, K. (2002) Three-dimensional structure of non-activated cGMP phosphodiesterase 6 and comparison of its image with those of activated forms. J. Struct. Biol. 139, 27-38 (Pubitemid 35304458)
6. Goc, A., Chami, M., Lodowski, D. T., Bosshart, P., Moiseenkova-Bell, V., Baehr, W., Engel, A., and Palczewski, K. (2010) Structural characterization of the rod cGMP phosphodiesterase 6. J. Mol. Biol. 401, 363-373
7. Gillespie, P. G., and Beavo, J. A. (1989) Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948. Mol. Pharmacol. 36, 773-781 (Pubitemid 20008225)
8. D'Amours, M. R., Granovsky, A. E., Artemyev, N. O., and Cote, R. H. (1999) Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme. Mol. Pharmacol. 55, 508-514 (Pubitemid 29128107)
9. Zhang, X., Feng, Q., and Cote, R. H. (2005) Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest. Ophthalmol. Vis. Sci. 46, 3060-3066 (Pubitemid 44264288)
10. Laties, A., and Sharlip, I. (2006) Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J. Sex. Med. 3, 12-27
11. Granovsky, A. E., and Artemyev, N. O. (2001) Partial reconstitution of photoreceptor cGMP phosphodiesterase characteristics in cGMP phosphodiesterase- 5. J. Biol. Chem. 276, 21698-21703
12. Zoraghi, R., Francis, S. H., and Corbin, J. D. (2007) Critical amino acids in phosphodiesterase-5 catalytic site that provide for high affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry 46, 13554-13563 (Pubitemid 350209951)
13. Granovsky, A. E., Natochin, M., McEntaffer, R. L., Haik, T. L., Francis, S. H., Corbin, J. D., and Artemyev, N. O. (1998) Probing domain functions of chimeric PDE6α'/PDE5 cGMP-phosphodiesterase. J. Biol. Chem. 273, 24485-24490 (Pubitemid 28454942)
14. Piriev, N. I., Yamashita, C. K., Shih, J., and Farber, D. B. (2003) Expression of cone photoreceptor cGMP-phosphodiesterase α' subunit in Chinese hamster ovary, 293 human embryonic kidney, and Y79 retinoblastoma cells. Mol. Vis. 9, 80-86 (Pubitemid 38097570)
15. White, J. B., Thompson, W. J., and Pittler, S. J. (2004) Characterization of 3′,5′ cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells. Absence of functional PDE6. Mol. Vis. 10, 738-749 (Pubitemid 41358220)
16. Zhang, J., Kuvelkar, R., Wu, P., Egan, R. W., Billah, M. M., and Wang, P. (2004) Differential inhibitor sensitivity between human recombinant and native photoreceptor cGMP-phosphodiesterases (PDE6s). Biochem. Pharmacol. 68, 867-873 (Pubitemid 39055994)
17. Muradov, H., Boyd, K. K., and Artemyev, N. O. (2006) Analysis of PDE6 function using chimeric PDE5/6 catalytic domains. Vision Res. 46, 860-868 (Pubitemid 43016116)
18. Muradov, H., Boyd, K. K., Haeri, M., Kerov, V., Knox, B. E., and Artemyev, N. O. (2009) Characterization of human cone phosphodiesterase-6 ectopically expressed in Xenopus laevis rods. J. Biol. Chem. 284, 32662-32669
19. Francis, S. H., Zoraghi, R., Kotera, J., Ke, H., Bessay, E. P., Blount, M. A., and Corbin, J. D. (2006) in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo, J. A., Francis, S. H., and Houslay, M. D., eds) pp. 131-164, CRC Press, Boca Raton, FL
20. Bischoff, E. (2004) Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 16, S11-S14
21. Kerr, N. M., and Danesh-Meyer, H. V. (2009) Phosphodiesterase inhibitors and the eye. Clin. Experiment Ophthalmol. 37, 514-523
22. Laties, A. M. (2009) Vision disorders and phosphodiesterase type 5 inhibitors. A review of the evidence to date. Drug Safety 32, 1-18
23. Supuran, C. T., Mastrolorenzo, A., Barbaro, G., and Scozzafava, A. (2006) Phosphodiesterase 5 inhibitors. Drug design and differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Curr. Pharm. Des. 12, 3459-3465 (Pubitemid 44400483)
24. Chen, G., Wang, H., Robinson, H., Cai, J., Wan, Y., and Ke, H. (2008) An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies. Biochem. Pharmacol. 75, 1717-1728
25. Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P. N., Artis, D. R., Bollag, G., Milburn, M. V., Kim, S. H., Schlessinger, J., and Zhang, K. Y. (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12, 2233-2247 (Pubitemid 39593200)
26. Sung, B. J., Hwang, K. Y., Jeon, Y. H., Lee, J. I., Heo, Y. S., Kim, J. H., Moon, J., Yoon, J. M., Hyun, Y. L., Kim, E., Eum, S. J., Park, S. Y., Lee, J. O., Lee, T. G., Ro, S., and Cho, J. M. (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425, 98-102 (Pubitemid 37101725)
27. Huai, Q., Liu, Y., Francis, S. H., Corbin, J. D., and Ke, H. (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 279, 13095-13101 (Pubitemid 38445887)
28. Wang, H., Ye, M., Robinson, H., Francis, S. H., and Ke, H. (2008) Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol. Pharmacol. 73, 104-110 (Pubitemid 350294201)
29. Carleton, K. L., Spady, T. C., and Cote, R. H. (2005) Rod and cone opsin families differ in spectral tuning domains but not signal transducing domains as judged by saturated evolutionary trace analysis. J. Mol. Evol. 61, 75-89 (Pubitemid 41188511)
30. Lichtarge, O., and Wilkins, A. (2010) Evolution.Aguide to perturb protein function and networks. Curr. Opin. Struct. Biol. 20, 351-359
31. Swofford, D. L. (2000) PAUP*. Phylogenetic Analysis Using Parsimony and Other Methods, Sinauer Associates, Sunderland, MA
32. Schwede, T., Kopp, J., Guex, N., and Peitsch, M. C. (2003) SWISS-MODEL. An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385 (Pubitemid 37442164)
33. Zhang, K. Y., Card, G. L., Suzuki, Y., Artis, D. R., Fong, D., Gillette, S., Hsieh, D., Neiman, J., West, B. L., Zhang, C., Milburn, M. V., Kim, S. H., Schlessinger, J., and Bollag, G. (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell 15, 279-286 (Pubitemid 38950974)
34. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291
35. Blount, M. A., Beasley, A., Zoraghi, R., Sekhar, K. R., Bessay, E. P., Francis, S. H., and Corbin, J. D. (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol. Pharmacol. 66, 144-152 (Pubitemid 38822097)
36. Rybalkin, S. D., Rybalkina, I. G., Shimizu-Albergine, M., Tang, X. B., and Beavo, J. A. (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J. 22, 469-478 (Pubitemid 36193592)
37. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
38. Cote, R. H. (2000) Kinetics and regulation of cGMP binding to noncatalytic binding sites on photoreceptor phosphodiesterase. Methods Enzymol. 315, 646-672
39. Trott, O., and Olson, A. J. (2010) AutoDock Vina. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461
40. Wang, H., Liu, Y., Huai, Q., Cai, J., Zoraghi, R., Francis, S. H., Corbin, J. D., Robinson, H., Xin, Z., Lin, G., and Ke, H. (2006) Multiple conformations of phosphodiesterase-5. Implications for enzyme function and drug development. J. Biol. Chem. 281, 21469-21479 (Pubitemid 44115485)
41. Francis, S. H., Sekhar, K. R., Ke, H., and Corbin, J. D. (2011) Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. Handb. Exp. Pharmacol. 200, 93-133